Mesut TEZ, Hakan ATAŞ, Birol KORUKLUOĞLU, Neşe YAKŞİ, Bülent ÇOMÇALI, Barış SAYLAM

Can preoperative modified systemic inflammation score (mSIS) be used to predict malignancy in persistent nondiagnostic thyroid nodules?

Background/aim: Despite the use of ultrasound guidance, a significant part of thyroid biopsies are nondiagnostic (ND). We aimed to investigate the utility of the preoperative modified systemic inflammation score (mSIS) to predict malignancies in patients with persistent ND thyroid nodules (TNs). Materials and methods: Records of 924 patients underwent thyroidectomy between September 2016 and May 2019 were retrospectively reviewed. The calculation of mSIS was as follows: mSIS 0 [patients with albumin (ALB) ≥ 4.0 g/dL and lymphocyte to monocyte ratio (LMR) ≥ 3.4], mSIS 1 [ALB < 4.0 g/dL or LMR < 3.4], and mSIS 2 [ALB < 4.0 g/dL and LMR < 3.4]. Results: One hundred and thirty-six patients were included in the study. Of the patients with a median age of 49 (21–81) years, 26 (19.1%) were male, and 110 (80.9%) were female. Besides low lymphocyte count (P = 0.03), and ALB levels (P < 0.01), higher BMI (P = 0.02) were also associated with malignancy. In patients classified as mSIS 2, 1 and 0; malignancy rates were 100%, 25.8%, and 16.1%, respectively. The association between preoperative mSIS and thyroid malignancies was statistically significant (P < 0.01). Conclusion: We recommend that when patients with persistent ND TNs are assigned to mSIS 2 or 1, surgery should not be delayed due to the risk of malignancy.Key words: Systemic inflammation score, thyroid nodules, malignancy, nondiagnostic, lymphocyte to monocyte ratio

PDF

___

1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26 (1): 1-133. doi: 10.1089/thy.2015.0020
2. Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid 2017; 27 (11): 1341-1346. doi: 10.1089/thy.2017.0500
3. Başer H, Topaloğlu O, Fakı S, Alkan A, Yazıcıoğlu MÖ et al. Evaluation of malignancy with thyroid imaging reporting and data system (TI-RADS) in thyroid nodules with persistent nondiagnostic cytology. Turkish Journal of Medical Sciences 2019; 49 (3): 907-913. doi: 10.3906/sag-1811-198
4. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454 (7203): 436‐444. doi: 10.1038/ nature07205
5. Jackson D, Handelsman RS, Farrá JC, Lew JI. Increased incidental thyroid cancer in patients with subclinical chronic lymphocytic thyroiditis. The Journal of Surgical Research 2020; 245: 115-118. doi: 10.1016/j.jss.2019.07.025
6. Kocer D, Karakukcu C, Karaman H, Gokay F, Bayram F. May the neutrophil/lymphocyte ratio be a predictor in the differentiation of different thyroid disorders? Asian Pasific Journal of Cancer Prevention 2015; 16 (9): 3875-3879. doi: 10.7314/apjcp.2015.16.9.3875
7. Li N, Fu S, Cui MM, Niu Y, Li B et al. Platelet distribution width and serum albumin levels for discrimination of thyroid cancer from benign thyroid nodules. Asian Pasific Journal of Cancer Prevention 2017; 18 (7): 1773-1777. doi: 10.22034/ APJCP.2017.18.7.1773
8. Yokota M, Katoh H, Nishimiya H, Kikuchi M, Kosaka Y et al. Lymphocyte-monocyte ratio significantly predicts recurrence in papillary thyroid cancer. The Journal of Surgical Research 2020; 246: 535-543. doi: 10.1016/j.jss.2019.09.034
9. Suzuki Y, Okabayashi K, Hasegawa H, Tsuruta M, Shigeta K et al. Comparison of preoperative inflammation-based prognostic scores in patients with colorectal cancer. Annals of Surgery 2018; 267 (3): 527-531. doi: 10.1097/SLA.0000000000002115
10. Nishijima TF, Muss HB, Shachar SS, Tamura K, Takamatsu Y. Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: a systematic review and meta-analysis. Cancer Treatment Reviews 2015; 41 (10): 971-978. doi: 10.1016/j.ctrv.2015.10.003
11. Chang Y, An H, Xu L, Zhu Y, Yang Y et al. Systemic inflammation score predicts postoperative prognosis of patients with clearcell renal cell carcinoma. British Journal of Cancer 2015; 113 (4): 626-633. doi: 10.1038/bjc.2015.241
12. Lin JX, Lin JP, Xie JW, Wang JB, Lu J et al. Prognostic importance of the preoperative modified systemic inflammation score for patients with gastric cancer. Gastric Cancer 2019; 22 (2): 403- 412. doi: 10.1007/s10120-018-0854-6
13. Ataş H, Korukluoğlu B, Özdemir BA, Yakşi N, Saylam B et al. Diagnostic value of modified systemic inflammation score for prediction of malignancy in patients with indeterminate thyroid nodules. American Journal of Surgery 2021; 221 (1): 117-121. doi: 10.1016/j.amjsurg.2020.08.002
14. Shibutani M, Maeda K, Nagahara H, Fukuoka T, Matsutani S et al. The prognostic value of the systemic inflammatory score in patients with unresectable metastatic colorectal cancer. Oncology Letters 2018; 16 (1): 666-672. doi: 10.3892/ ol.2018.8628
15. Liu B, Huang Y, Sun Y, Zhang J, Yao Y et al. Prognostic value of inflammation-based scores in patients with osteosarcoma. Scientific Reports 2016; 6: 39862. doi: 10.1038/srep39862
16. Kanda M, Koike M, Tanaka C, Kobayashi D, Hattori N et al. modified systemic inflammation score is useful for risk stratification after radical resection of squamous cell carcinoma of the esophagus. Annals of Surgical Oncology 2019; 26 (13): 4773-4781. doi: 10.1245/s10434-019-07914-7
17. Ghoshal A, Garmo H, Arthur R, Carroll P, Holmberg L et al. Thyroid cancer risk in the Swedish AMORIS study: the role of inflammatory biomarkers in serum. Oncotarget 2017; 9 (1): 774-782. doi: 10.18632/oncotarget.22891
18. Yoon JH, Lee HS, Kim EK, Moon HJ, Kwak JY. Thyroid nodules: nondiagnostic cytologic results according to thyroid imaging reporting and data system before and after application of the Bethesda system. Radiology 2015; 276 (2): 579-587. doi: 10.1148/radiol.15142308
19. Son H, Lee H, Kang K, Lee I. The risk of thyroid cancer and obesity: a nationwide population-based study using the Korea National Health Insurance Corporation cohort database. Surgical Oncology 2018; 27 (2): 166-171. doi: 10.1016/j. suronc.2018.03.001